Altimmune, Inc. — Director's Dealing 2022

Jun 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-06-27

Reporting Person: Jorkasky Diane (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-27	Common Stock, par value $0.0001	M	17610	$3.15	Acquired	17610	Direct
2022-06-27	Common Stock, par value $0.0001	S	17610	$11.7515	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-27	Stock Options (option to buy)	$3.15	M	17610	Disposed	2030-05-11	Common Stock, par value $0.0001 (40000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $11.88, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments, subject to the reporting person's continued service through the applicable vesting date.